Physician profile
Gregory J Litton
NPI 1487603916
$98,831.33
in general payments reported to CMS, 2019-2025
50 companies · $1,800 in 2025
The $1,800 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,327 · 2020: $22K · 2021: $21K · 2022: $19K · 2023: $28K · 2024: $2,997 · 2025: $1,800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $23K · Consulting Fee: $3,564 · Food and Beverage: $3,504 · Travel and Lodging: $1,751 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $23,425.00 |
| Consulting Fee | $3,564.00 |
| Food and Beverage | $3,504.01 |
| Travel and Lodging | $1,751.00 |
| Education | $124.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cornerstone Specialty Network LLC | $48,582.95 | 2019-2024 | |
| Daiichi Sankyo INC. | $38,509.06 | 2020-2025 | Enhertu |
| Astellas Pharma US INC | $5,853.98 | 2021-2023 | Padcev |
| Geron Corporation | $822.21 | 2025 | Rytelo |
| Deciphera Pharmaceuticals INC. | $800.00 | 2021 | |
| Athenex Pharmaceutical Division, LLC | $600.00 | 2020 | |
| Foundation Medicine, INC. | $351.42 | 2019 | |
| Genentech USA, INC. | $225.24 | 2019-2025 | Phesgo, Perjeta, Tecentriq |
| Astrazeneca Pharmaceuticals LP | $213.39 | 2022-2025 | Imfinzi, Lynparza, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $211.51 | 2019-2025 | Opdivo, Eliquis |
| Janssen Biotech, INC. | $207.05 | 2019-2023 | Erleada |
| Novartis Pharmaceuticals Corporation | $200.53 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $180.15 | 2022-2025 | Libtayo |
| Celgene Corporation | $162.27 | 2022-2025 | Reblozyl, Pomalyst, Opdualag |
| Aveo Pharmaceuticals, INC. | $135.37 | 2022-2025 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $131.14 | 2021-2025 | Bavencio |
| Pfizer INC. | $125.02 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $116.92 | 2022-2025 | Gilotrif |
| Merck Sharp & Dohme LLC | $101.93 | 2024-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Genzyme Corporation | $91.37 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.25 | 2024 | Ninlaro, Fruzaqla |
| Incyte Corporation | $78.83 | 2023-2025 | Jakafi, Monjuvi |
| Eisai INC. | $77.89 | 2023-2025 | |
| Abbvie INC. | $76.59 | 2022-2025 | |
| Lilly USA, LLC | $76.35 | 2023-2024 | Verzenio, Jaypirca |
| Tersera Therapeutics LLC | $67.31 | 2023-2024 | Zoladex |
| Sumitomo Pharma America, INC. | $63.84 | 2023-2024 | Orgovyx |
| Bayer Healthcare Pharmaceuticals INC. | $62.84 | 2024-2025 | |
| Gilead Sciences, INC. | $59.70 | 2021-2025 | Trodelvy |
| Seagen INC. | $54.41 | 2022-2023 | Adcetris |
| Pharmacyclics LLC, An Abbvie Company | $46.47 | 2023 | Imbruvica |
| Amgen INC. | $44.91 | 2022-2023 | Lumakras |
| Sobi, INC | $40.05 | 2025 | |
| Medtronic, INC. | $33.65 | 2023-2024 | Osteocool Rf Ablation System, Synchromedii |
| Genentech, INC. | $31.58 | 2022 | |
| Adc Therapeutics America, INC. | $27.38 | 2025 | |
| Myriad Genetic Laboratories, INC. | $26.69 | 2024 | Myrisk |
| Adaptive Biotechnologies Corporation | $25.50 | 2023 | Clonoseq |
| Iovance Biotherapeutics, INC. | $23.53 | 2025 | Amtagvi |
| Jazz Pharmaceuticals INC. | $23.46 | 2024 | |
| Azurity Pharmaceuticals, INC. | $23.16 | 2025 | Danziten |
| Stemline Therapeutics INC. | $21.00 | 2024 | Orserdu |
| Glaxosmithkline, LLC. | $19.42 | 2025 | Zejula, Jemperli |
| Puma Biotechnology, INC. | $18.40 | 2024 | |
| Syndax Pharmaceuticals, INC. | $17.75 | 2025 | Revuforj |
| Cycle Pharmaceuticals INC | $16.99 | 2025 | Phyrago |
| Karyopharm Therapeutics INC. | $15.91 | 2024 | Xpovio |
| G1 Therapeutics, INC. | $15.78 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $15.04 | 2025 | Onivyde |
| Myovant Sciences INC. | $14.14 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$55,970.81 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Litton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.